Immunocellular Therapy
Cancer Immune Cell Therapy
Although traditional cancer medical treatment have made significant progress, such as surgery, chemotherapy, radiotherapy, and even in recent years, immune target drug therapy can effectively control most of the early stage of cancer, however, when cancer is already at an advanced stage with metastasis, progressed disease and recurrent, or when the patient's malignancy is ineffective or resistant to the above standard treatments, physicians can only do nothing without better therapeutic strategies.
With the continuous progress in recent years, immune cell therapy has become another breakthrough development in cancer treatment, and it has gradually become a new trend in cancer combination therapy, autologous immune cell therapy is characterized by a high safety and a low risk of side effects. In September 2018, the Ministry of Health and Welfare announced the implementation of the “Regulations Governing the Application or Use of Specific Medical Techniques or Examinations, or Medical Devices” (referred to as the “Regulations of Special Medical Techniques”), classify 6 cell therapies with determinable safety and predictable results as specific medical technologies, which not only accelerates the development of autologous immune cell therapy technology and improves the quality of clinical services, meanwhile also covers the following patients: (1). Stages I to III solid cancers, those who fail to respond to standard treatment (2). Stage IV solid cancers(3). Hematological malignancies which fail to respond to standard therapy. These approved programs and indications cover almost all types of cancer treatment, which also provides better combination treatment options for cancer patients, thereby improving the success rate of cancer treatment and the quality of life.
In response to the development trend of cancer immune cell therapy, Kao-ho Hospital has invested a lot of professional manpower and resources in the research and development of cancer immune cell therapy for many years. In July 2022, it was officially approved by the Ministry of Health and Welfare as a qualified medical institution for autologous immune cell therapy, planning and preparing personalized immune cell therapy for cancer patients, the immune cell preparations are returned to the body to precisely attack and destroy tumor cells to achieve the purpose of personalized precision medicine. Under the good regulation and supervision of the “Regulations of Special Medical Techniques”, the technology of cancer immune cell therapy will provide another chance for more advanced stage cancer patients or those who have failed traditional standard treatment to overcome cancers.
Indications
Lung Cancer
Liver Cancer
Breast Cancer
Ovarian Cancer
Colorectal Cancer
Head and Neck Cancers
Stomach Cancer
Kidney Cancer
National-grade GTP Laboratory
International-level high-standard cell laboratory
The national-grade laboratory met Good Tissue Practice (GTP) standard with high demand on hardware,including positive pressure laboratory,clean room with cleanliness reaching Class 10000,P3-level biosafety cabinet,independent ventilation,complete separated flow of people and objects,constant temperature and humidity.
MOHW approved GTP laboratory for human cell and tissue,with the permit to perform clinical trials.
